PUMA BIOTECHNOLOGY, INC. (PBYI) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.42B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-45.00K; Retained Earnings (Accumulated Deficit)USD $-1.28B.
- 2026-03-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.42B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-31.00K; Retained Earnings (Accumulated Deficit)USD $-1.29B.
- 2025-12-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.41B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $36.00K; Retained Earnings (Accumulated Deficit)USD $-1.28B.
- 2025-09-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.41B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $19.00K; Retained Earnings (Accumulated Deficit)USD $-1.30B.
PUMA BIOTECHNOLOGY, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00K | $1.42B | $-45.00K | $-1.28B | $138.54M | (m) | 3 month · $1.95M 6 month · $3.85M | (m) | (m) | (m) |
| 2026-03-31 | $5.00K | $1.42B | $-31.00K | $-1.29B | $128.42M | (m) | 3 month · $1.90M | (m) | (m) | (m) |
| 2025-12-31 | $5.00K | $1.41B | $36.00K | $-1.28B | $130.34M | (m) | 12 month · $6.94M | (m) | (m) | (m) |
| 2025-09-30 | $5.00K | $1.41B | $19.00K | $-1.30B | $115.27M | (m) | 3 month · $1.67M 9 month · $5.33M | (m) | (m) | (m) |
| 2025-06-30 | $5.00K | $1.41B | $-14.00K | $-1.31B | $104.72M | (m) | 3 month · $1.63M 6 month · $3.65M | (m) | (m) | (m) |
| 2025-03-31 | $5.00K | $1.41B | $-11.00K | $-1.31B | $97.11M | (m) | 3 month · $2.03M | (m) | (m) | (m) |
| 2024-12-31 | $5.00K | $1.41B | $6.00K | $-1.31B | $92.12M | (m) | 12 month · $8.24M | (m) | (m) | (m) |
| 2024-09-30 | $5.00K | $1.41B | $26.00K | $-1.33B | $71.09M | (m) | 3 month · $2.05M 9 month · $6.49M | (m) | (m) | (m) |
| 2024-06-30 | $5.00K | $1.40B | $-32.00K | $-1.35B | $48.51M | (m) | 3 month · $2.06M 6 month · $4.44M | (m) | (m) | (m) |
| 2024-03-31 | $5.00K | $1.40B | $-26.00K | $-1.35B | $50.98M | (m) | 3 month · $2.38M | (m) | (m) | (m) |
| 2023-12-31 | $5.00K | $1.40B | $-4.00K | $-1.35B | $53.44M | (m) | 12 month · $10.25M | (m) | (m) | (m) |
| 2023-09-30 | $5.00K | $1.40B | $-4.00K | $-1.36B | $38.74M | (m) | 3 month · $2.54M 9 month · $7.82M | (m) | (m) | (m) |
| 2023-06-30 | $5.00K | $1.39B | $-6.00K | $-1.36B | $30.40M | (m) | 3 month · $2.43M 6 month · $5.27M | (m) | (m) | (m) |
| 2023-03-31 | $5.00K | $1.39B | (m) | $-1.37B | $25.85M | (m) | 3 month · $2.84M | (m) | (m) | (m) |
| 2022-12-31 | $5.00K | $1.39B | $0.00 | $-1.37B | $21.61M | 12 month · $200.00K | 12 month · $11.83M | (m) | (m) | (m) |
| 2022-09-30 | $5.00K | $1.38B | $0.00 | $-1.36B | $22.16M | 3 month · $100.00K 9 month · $200.00K | 3 month · $2.83M 9 month · $9.20M | (m) | (m) | (m) |
| 2022-06-30 | $5.00K | $1.38B | $0.00 | $-1.36B | $19.74M | 3 month · $200.00K 6 month · $200.00K | 3 month · $3.22M 6 month · $6.37M | (m) | (m) | (m) |
| 2022-03-31 | $4.00K | $1.38B | $-1.00K | $-1.37B | $7.14M | 3 month · $200.00K | 3 month · $3.15M | (m) | (m) | (m) |
| 2021-12-31 | $4.00K | $1.36B | $-2.00K | $-1.37B | $-2.45M | (m) | 12 month · $32.63M | (m) | (m) | (m) |
| 2021-09-30 | $4.00K | $1.36B | $-2.00K | $-1.37B | $-10.92M | (m) | 3 month · $4.28M 9 month · $28.38M | (m) | (m) | (m) |
| 2021-06-30 | $4.00K | $1.36B | $-1.00K | $-1.33B | $29.47M | (m) | 3 month · $18.24M 6 month · $24.10M | (m) | (m) | (m) |
| 2021-03-31 | $4.00K | $1.34B | (m) | $-1.32B | $16.34M | (m) | 3 month · $5.86M | (m) | (m) | (m) |
| 2020-12-31 | $4.00K | $1.33B | $0.00 | $-1.34B | $-5.95M | (m) | 12 month · $36.58M | (m) | (m) | (m) |
| 2020-09-30 | $4.00K | $1.32B | (m) | $-1.32B | $-453.00K | (m) | 3 month · $7.57M 9 month · $27.10M | (m) | (m) | (m) |
| 2020-06-30 | $4.00K | $1.31B | $1.00K | $-1.29B | $23.40M | (m) | 3 month · $10.63M 6 month · $19.54M | (m) | (m) | (m) |
| 2020-03-31 | $4.00K | $1.30B | $2.00K | $-1.29B | $9.38M | (m) | 3 month · $8.91M | (m) | (m) | (m) |
| 2019-12-31 | $4.00K | $1.30B | $62.00K | $-1.28B | $17.46M | (m) | 12 month · $57.33M | (m) | (m) | (m) |
| 2019-09-30 | $4.00K | $1.28B | $115.00K | $-1.27B | $17.18M | (m) | 3 month · $12.21M 9 month · $45.79M | (m) | (m) | (m) |
| 2019-06-30 | $4.00K | $1.27B | $110.00K | $-1.25B | $21.77M | (m) | 3 month · $15.44M 6 month · $33.58M | (m) | (m) | (m) |
| 2019-03-31 | $4.00K | $1.26B | $20.00K | $-1.21B | $43.47M | (m) | 3 month · $18.14M | (m) | (m) | (m) |
| 2018-12-31 | $4.00K | $1.24B | $-12.00K | $-1.20B | $34.31M | (m) | 12 month · $86.94M | (m) | (m) | (m) |
| 2018-09-30 | $4.00K | $1.22B | $-3.00K | $-1.17B | $45.91M | (m) | 3 month · $20.81M 9 month · $68.34M | (m) | (m) | (m) |
| 2018-06-30 | $4.00K | $1.20B | $-1.00K | $-1.16B | $38.30M | (m) | 3 month · $22.18M 6 month · $47.54M | (m) | (m) | (m) |
| 2018-03-31 | $4.00K | $1.17B | (m) | $-1.11B | $57.46M | (m) | 3 month · $25.35M | (m) | (m) | (m) |
| 2017-12-31 | $4.00K | $1.14B | (m) | $-1.09B | $53.30M | (m) | 12 month · $108.73M | (m) | (m) | (m) |
| 2017-09-30 | $4.00K | $1.11B | $-7.00K | $-1.02B | $79.17M | (m) | 9 month · $83.21M | (m) | (m) | (m) |
| 2017-06-30 | $4.00K | $1.07B | $-25.00K | $-947.21M | $120.11M | (m) | 6 month · $56.72M | (m) | (m) | (m) |
| 2017-03-31 | $4.00K | $1.04B | $-50.00K | $-869.38M | $167.39M | (m) | 3 month · $29.76M | (m) | (m) | (m) |
| 2016-12-31 | $4.00K | $1.01B | $-13.00K | $-796.51M | $209.82M | (m) | 12 month · $117.26M | (m) | (m) | (m) |
| 2016-09-30 | $3.00K | $814.99M | $3.00K | $-723.85M | $91.15M | (m) | 9 month · $87.99M | (m) | (m) | (m) |
| 2016-06-30 | $3.00K | $785.11M | $31.00K | $-658.07M | $127.08M | (m) | 6 month · $58.24M | (m) | (m) | (m) |
| 2016-03-31 | $3.00K | $756.38M | $29.00K | $-591.47M | $164.94M | (m) | 3 month · $29.51M | (m) | (m) | (m) |
| 2015-12-31 | $3.00K | $726.65M | $-147.00K | $-520.50M | $206.01M | (m) | 12 month · $94.93M | (m) | (m) | (m) |
| 2015-09-30 | $3.00K | $703.65M | $-32.00K | $-458.78M | $244.84M | (m) | 9 month · $73.25M | (m) | (m) | (m) |
| 2015-06-30 | $3.00K | $673.50M | $-181.00K | $-398.36M | $274.78M | (m) | 6 month · $48.30M | (m) | (m) | (m) |
| 2015-03-31 | $3.00K | $638.09M | $-89.00K | $-333.67M | $304.34M | (m) | 3 month · $20.10M | (m) | (m) | (m) |
| 2014-12-31 | $3.00K | $399.19M | $-95.00K | $-281.22M | $117.05M | (m) | 12 month · $39.15M | (m) | (m) | (m) |
| 2014-09-30 | $3.00K | $375.45M | $-118.00K | (m) | $141.60M | (m) | 9 month · $22.78M | (m) | (m) | (m) |
| 2014-06-30 | $3.00K | $365.00M | $-77.00K | (m) | $167.04M | (m) | 6 month · $12.33M | (m) | (m) | (m) |
| 2014-03-31 | $3.00K | $357.83M | $-6.00K | (m) | $198.79M | (m) | 3 month · $5.16M | (m) | (m) | (m) |
| 2013-12-31 | $3.00K | $223.23M | $3.00K | $-139.25M | $83.99M | (m) | 12 month · $7.52M | (m) | (m) | (m) |
| 2013-09-30 | $3.00K | $218.07M | $-8.00K | (m) | $94.76M | (m) | 9 month · $4.43M | (m) | (m) | (m) |
| 2013-06-30 | $3.00K | $216.12M | $-74.00K | (m) | $107.03M | (m) | 6 month · $2.62M | (m) | (m) | (m) |
| 2013-03-31 | $3.00K | $214.67M | $-25.00K | (m) | $118.28M | (m) | 3 month · $1.18M | (m) | (m) | (m) |
| 2012-12-31 | $3.00K | $213.50M | (m) | (m) | $128.91M | (m) | 12 month · $1.41M | (m) | 12 month · $18.22M | (m) |
| 2012-09-30 | $2.00K | $71.68M | (m) | (m) | $9.00M | (m) | 9 month · $820.05K | (m) | 9 month · $6.25M | (m) |
| 2012-06-30 | $2.00K | $64.86M | (m) | (m) | $28.04M | (m) | 6 month · $461.77K | (m) | 6 month · $-214.59K | (m) |
| 2012-03-31 | $2.00K | $64.66M | (m) | (m) | $42.60M | (m) | 3 month · $198.06K | (m) | 3 month · $-149.28K | (m) |
| 2011-12-31 | $2.00K | $64.61M | (m) | (m) | $54.37M | (m) | 12 month · $67.00K | (m) | 12 month · $7.59M | 12 month · $61.00K |
| 2011-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $1.80M | (m) |
| 2011-09-30 | $400.00 | $68.51K | (m) | (m) | $-323.66K | (m) | (m) | (m) | (m) | 9 month · $61.98K |
| 2011-06-30 | $300.00 | $70.35K | (m) | (m) | $-1.53K | (m) | 6 month · $8.20K | $0.00 | (m) | (m) |
| 2010-12-31 | $400.00 | $6.53K | (m) | (m) | $462.00 | (m) | 12 month · $16.30K | $0.00 | (m) | 4 month · $7.00K 4 month · $6.53K |
| 2010-09-15 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | $138.00 | (m) | 12 month · $19.15K | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | $-2.18K | (m) | 12 month · $10.50K | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | $1.41K | (m) | 8 month · $4.50K | (m) | (m) | (m) |
| 2007-04-26 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |